By Spondylitis Association of America
New evidence, presented by Alexander Egeberg, MD, PhD, University of Copenhagen, and colleagues in the Journal of the American Academy of Dermatology suggests that patients with psoriasis or any related form of the condition, such as psoriatic arthritis, have a higher risk of experiencing a cardiovascular disease event (CVD) compared to non-afflicted individuals.
Chances are, if you are living with spondyloarthritis, you have taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs,) as they are the most widely used class of medications for spondyloarthritis symptom relief. You are also likely aware that all NSAIDs carry some risk of major toxicity. A recent study now suggests that some NSAIDs carry higher risks for older adults who take NSAIDs regularly.
Biologic medications can play an important role for those living with spondyloarthritis. They may slow the progression of the disease, treat joint/spinal arthritic pain, and can generally alleviate many symptoms. However, like all medications, they have drawbacks for those taking them - one being that patients on biologics can’t receive live vaccines - including, until very recently, the Shingles vaccine.
On October 20th, 2017 Janssen Biotech, Inc. announced that the FDA has approved SIMPONI ARIA (IV administered golimumab) for the treatment of adults with active ankylosing spondylitis (AS) or active psoriatic arthritis (PsA.)
One of the larger challenges involved in treating ankylosing spondylitis (AS) is the varying effects of, and responses to, available medications. Currently, Tumor Necrosis Factors (TNF) inhibitors are the standard of care for most patients with moderate to severe AS, and, as with any form of organic medication, their effectiveness can be influenced by various biological factors.
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616